Cue Health was the first company to make an over-the-counter COVID-19 molecular diagnostic test for at-home use that received FDA approval, according to the Aug. 10 Cue news release.
Three takeaways from the report:
- Cue Health’s second-quarter revenue was $87.7 million.
- This revenue number exceeded expectations largely because of higher-than-expected COVID-19 testing orders.
- Private sector revenue made up 91.8 percent of Cue’s second-quarter revenue.
